GRAIL, Inc. Investigation- GRAL
Case Summary
Investors who suffered a loss and would like to learn more, click here to contact us.
Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving GRAIL, Inc. (NASDAQ: GRAL).
If you have information that could assist in the GRAIL investigation or if you are a GRAIL investor who suffered a loss and would like to learn more, you can provide your information in the form on this page. You can also contact attorney J.C. Sanchez of Robbins Geller by calling 800/449-4900 or via e-mail at info@rgrdlaw.com.
THE COMPANY: GRAIL is a commercial-stage healthcare company, providing multi-cancer early detection testing and services.
THE REVELATION: On February 19, 2026, GRAIL announced results for its NHS-Galleri trial, which evaluated annual multi-cancer screening with GRAIL’s Galleri test, revealing that “[t]he primary endpoint of statistically significant Stage III-IV reduction was not observed.” On this news, the price of GRAIL stock fell significantly.
ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world’s leading law firms representing investors in securities fraud and shareholder rights litigation. Our Firm ranked #1 on the most recent ISS Securities Class Action Services Top 50 Report, recovering more than $916 million for investors in 2025. This marks our fourth #1 ranking in the past five years. And in those five years alone, Robbins Geller recovered $8.4 billion for investors – $3.4 billion more than any other law firm. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs’ firms in the world, and the Firm’s attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig.